SANTA CLARA, Calif. & MADISON, Wis.–Agilent Technologies Inc. (NYSE:A – News) and Stemina Biomarker Discovery, Inc. today announced efforts to accelerate Stemina’s metobolomic research. Stemina uses metabolomic analysis of stem cells for the discovery of biomarkers for use in drug screening and drug development.

Agilent is providing a 1290 Infinity UHPLC system to separate stem cellular metabolites, coupled to a 6530 Accurate Mass quadrupole time-of-flight mass spectrometer (Q-TOF MS) to identify those metabolites. Agilent also is providing Mass Profiler Professional software to help Stemina researchers interpret the complex data generated by metabolomics experiments.

“We are pleased to broaden our relationship with Agilent to advance our scientific platform and our discovery of important small molecules involved in developmental toxicity and autism,” said Beth Donley, Stemina CEO. “We have used Agilent technology since Stemina began operations in 2007 and have been very pleased with the instrumentation, support and collaboration we have experienced with Agilent.”

“Metabolomics is a major growth area for us, and the innovative work being done at Stemina is the kind we like to support,” said Gustavo Salem, Agilent vice president and general manager, Biological Systems Division. “We’ve aggressively built an LC/MS portfolio for the life sciences in recent years, and the Mass Profiler Professional software provides the crucial ability to visualize biological pathways from the massive and complex data sets generated by metabolomics studies.”

About Stemina Biomarker Discovery, Inc.

The Stemina research team, founded on research by Chief Scientific Officer Gabriela Cezar, D.V.M., Ph.D., Chief Scientific Officer, is focused on the discovery, development and commercialization of molecular biomarkers to improve drug safety and human health. Paul R. West, Ph.D., is the company’s Director of BioAnalytical Chemistry. Stemina’s cell based assays arise from the strategic convergence of two cutting edge technologies: human embryonic stem (hES) cells and metabolomics. Stemina uses Agilent mass spectrometry systems to analyze the small molecules secreted by hES cells, and differentiated cells such as heart and neural cells made from hES cells, in response to drugs, injury or disease. The company’s research has made significant progress in metabolomic profiling of human embryonic stem cell response to dosing with pharmaceutical agents. The result of this work is “devTox™”, an assay to screen pharmaceutical agents for teratogenicity. Information about Stemina is available at www.stemina.com.

About Agilent Technologies

Agilent Technologies Inc. (NYSE:A – News) is the world’s premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company’s 16,000 employees serve customers in more than 110 countries. Agilent had net revenues of $4.5 billion in fiscal 2009. Information about Agilent is available on the Web at www.agilent.com.